Thank you for following our coverage on the coronavirus crisis, to stay updated on the latest Covid-19-related news, click here here.
As per the understanding, Ocugen will have US rights to the vaccine candidate and, in collaboration with Bharat Biotech, will be responsible for clinical development, registration, and commercialisation for the US market.
The survey, conducted by Gaon Connection among 6,040 rural respondents across 60 districts in 16 states and one union territory, found that 36 per cent said they would not want to pay for it. The remaining 20 per cent said they are yet to decide on paying for the vaccine.
Bharat Biotech has already produced about 10 million doses of its still-in-trials Covaxin shot, ahead of an anticipated roll out by the middle of next year. It has a current annual capacity of 300 million vaccines and expects the first 100 million to be deployed by India, which has partly financed the development.
"During this crisis, the entire world understood that the real superman is our doctors, nurses and paramedical staff. I am the Defence Minister. And, I urge you to come forward and render your services to the armed forces," Singh said while addressing the foundation day programme of King George's Medical University (KGMU) through video-conferencing.